

# Hysterectomy for Benign Gynecologic Disease: In-hospital Use of Opioid and Non-opioid Analgesics

Pub Summary

2024

# Hysterectomy for benign gynecologic disease: in-hospital use of opioid and non-opioid analgesics

Systematic review using the Premier Healthcare database (PHD) to compare the in-hospital use of opioid and non-opioid analgesics in patients who underwent robotic-assisted hysterectomy (RH) vs. open (OH), vaginal (VH), or laparoscopic hysterectomy (LH) for benign gynecologic disease.

Study included 626,804 patients who underwent hysterectomy for benign gynecologic disease between January 1, 2013 and December 31, 2019. Propensity score methods were used to create cohorts stratified to inpatients vs. outpatients and based on the surgical approach.

**“Substance use disorders related to opioid prescription represent a public health emergency.”**

Surgical procedures with subsequent persistent opioid use in approximately 3-8% of patients.”

**da Vinci Hysterectomy was associated with lower median total doses of administered opioids than the other surgical approaches for both inpatients and outpatients on the day of surgery**

(each  $p < 0.001$ ) with the largest difference observed between da Vinci hysterectomy and open hysterectomy.



Garzon S., Mariani A., Weaver A., et al. Robotic-assisted hysterectomy for benign gynecologic disease in the United States: in-hospital use of opioid and non-opioid analgesics. Journal of Robotic Surgery, 15 March 2024. <https://doi.org/10.1007/s11701-024-01948-0>

# Important safety information

## **Important safety information**

Serious complications may occur in any surgery, including da Vinci surgery, up to and including death. Serious risks include, but are not limited to, injury to tissues and organs and conversion to other surgical techniques which could result in a longer operative time and/or increased complications. For summary of the risks associated with surgery refer to [www.davincisurgery.com/safety](http://www.davincisurgery.com/safety) or [www.intuitive.com/safety](http://www.intuitive.com/safety).

For product intended use and/or indications for use, risks, cautions, and warnings and full prescribing information, refer to the associated user manual(s) or visit <https://manuals.intuitivesurgical.com/market>.

Individual outcomes may depend on a number of factors—including but not limited to—patient characteristics, disease characteristics, and/or surgeon experience.

## **Da Vinci Xi/X precaution statement**

The demonstration of safety and effectiveness for the representative specific procedures did not include evaluation of outcomes related to the treatment of cancer (overall survival, disease-free survival, local recurrence), except for radical prostatectomy which was evaluated for overall survival, or treatment of the patient's underlying disease/condition. Device usage in all surgical procedures should be guided by the clinical judgment of an adequately trained surgeon.

## **Privacy notice**

Intuitive's Privacy Notice is available at [www.intuitive.com/privacy](http://www.intuitive.com/privacy).

© 2024 Intuitive Surgical Operations, Inc. All rights reserved. Product names are trademarks or registered trademarks of Intuitive Surgical or their respective owner.

INTUITIVE